ImmunityBio's sBLA for Anktiva was unexpectedly rejected by the FDA, contradicting prior positive feedback and approval for a ...

Shares of ImmunityBio, Inc. (IBRX) tumbled 18% on Monday afternoon after the company announced that it received a Refuse to ...

ImmunityBio's ANKTIVA sBLA for papillary bladder cancer was rejected by the FDA despite prior support, prompting the company ...

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that the Company received a Refusal to ...

In this article, we are going to take a look at where ImmunityBio, Inc. (NASDAQ:IBRX) stands against other low risk high reward stocks set to triple by 2030. The market is getting tough these days ...

ImmunityBio, Inc.’s IBRX share price has dipped by 9.48%, which has investors questioning if this is right time to buy.

ImmunityBio, Inc. faces stock decline amid fundraising and market selloff. Click to read more on the long-term potential of ...

CULVER CITY, Calif., May 05, 2025--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that the Company received a Refusal to File (RTF) letter from the U.S. Food ...

We recently published a list of 10 Low Risk High Reward Stocks Set to Triple by 2030. In this article, we are going to take a ...

ImmunityBio (IBRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.